Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects

NCT01002417 is registered in ClinicalTrials.gov with Health Ever Bio-Tech Co., Ltd. as lead sponsor.

NCT NCT01002417
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01002417 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Study to Establish the Dosage, Efficacy, and Safety of MCS-2 in Treating Lower Urinary Tract Symptoms Suggestive of BPH in Treatment-Naive Male Subjects
Lead sponsor
Health Ever Bio-Tech Co., Ltd.
Phase
Phase 2/3
Overall status
Completed
Start date
July 31, 2010
Completion date
February 28, 2014
Enrollment
274 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, lower urinary tract symptoms